TRAIL on trial: preclinical advances in cancer therapy.
Daniel W. Stuckey,Khalid Shah +1 more
TLDR
How TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models are discussed.About:
This article is published in Trends in Molecular Medicine.The article was published on 2013-11-01 and is currently open access. It has received 241 citations till now. The article focuses on the topics: Targeted therapy.read more
Citations
More filters
Journal ArticleDOI
Stem cell-based therapies for cancer treatment: separating hope from hype
Daniel W. Stuckey,Khalid Shah +1 more
TL;DR: This perspective considers the current status of stem cell-based treatments for cancer and provides a rationale for translating the most promising preclinical studies into the clinic.
Journal ArticleDOI
Cancer stem cell targeted therapy: progress amid controversies
Tao Wang,Tao Wang,Sarah Shigdar,Michael P. Gantier,Michael P. Gantier,Yingchun Hou,Li Wang,Yong Li,Hadi Al. Shamaileh,Wang Yin,Shu-Feng Zhou,Xinhan Zhao,Wei Duan +12 more
TL;DR: The current status and progresses of cancer stem cells theory is illustrated and via providing a panoramic view of cancer therapy, the recent controversies regarding the feasibility of cancerstem cells targeted anti-cancer therapy are addressed.
Journal ArticleDOI
Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
TL;DR: Classes of nucleic acids, hurdles that must be overcome for effective intracellular delivery, types of nonviral nanomaterials used as delivery vehicles, and the different strategies that can be employed to target nucleic acid delivery specifically to tumor cells are discussed.
Journal ArticleDOI
Stem cells in cancer therapy: opportunities and challenges.
TL;DR: This review focuses on recent progress toward stem cell-based cancer treatments, and summarizes treatment advantages, opportunities, and shortcomings, potentially helping to refine future trials and facilitate the translation from experimental to clinical studies.
Journal ArticleDOI
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
Pedro P.G. Guimarães,Pedro P.G. Guimarães,Stephanie Gaglione,Tomasz Sewastianik,Ruben D. Carrasco,Ruben D. Carrasco,Robert Langer,Michael J. Mitchell +7 more
TL;DR: The design and implementation of nanoparticles to enhance TRAIL-based cancer therapy are reviewed and valuable insight is provided into guiding the design of future nanoparticle-based TRAIL cancer therapeutics to potentially enable future translation into the clinic.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Hallmarks of cancer: the next generation.
TL;DR: Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.
Journal ArticleDOI
Identification and characterization of a new member of the TNF family that induces apoptosis
Steven R. Wiley,Ken Schooley,Pamela J. Smolak,Wenie S. Din,Chang-Pin Huang,Jillian Nicholl,Grant R. Sutherland,Terri Davis Smith,Charles Rauch,Craig A. Smith,Raymond G. Goodwin +10 more
TL;DR: A novel tumor necrosis factor (TNF) family member has been cloned and characterized, and the TRAIL gene is located on chromosome 3 at position 3q26, which is not close to any other known TNF ligand family members.
Journal ArticleDOI
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
Henning Walczak,Robert E. Miller,Kiley Ariail,Brian Gliniak,Thomas S. Griffith,Marek Kubin,Wilson Chin,Jon Jones,Anne Woodward,Tiep Le,Craig A. Smith,Pam J. Smolak,Raymond G. Goodwin,Charles Rauch,JoAnn C. L. Schuh,David H. Lynch +15 more
TL;DR: Recurrent treatments with LZ–huTRAIL actively suppressed growth of the TRAIL–sensitive human mammary adenocarcinoma cell line MDA–231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with Lz–hu TRAIL demonstrated clear areas of apoptotic necrosis within 9–12 hours of injection.
Journal ArticleDOI
Apoptosis: a link between cancer genetics and chemotherapy.
TL;DR: Understanding the molecular events that contribute to drug-induced apoptosis, and how tumors evade apoptotic death, provides a paradigm to explain the relationship between cancer genetics and treatment sensitivity and should enable a more rational approach to anticancer drug design and therapy.